Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Clarithromycin | hsa00010 | Glycolysis / Gluconeogenesis | 3.09E-03 | 2 | P51648, P28332 | ALDH3A2, ADH6 | More | | Clarithromycin | hsa00052 | Galactose metabolism | 6.39E-04 | 2 | P06280, O43451 | GLA, MGAM | More | | Clarithromycin | hsa00053 | Ascorbate and aldarate metabolism | 4.51E-02 | 1 | P51648 | ALDH3A2 | More | | Clarithromycin | hsa00071 | Fatty acid degradation | 3.09E-03 | 2 | P28332, P51648 | ADH6, ALDH3A2 | More | | Clarithromycin | hsa00310 | Lysine degradation | 7.50E-04 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Clarithromycin | hsa00330 | Arginine and proline metabolism | 4.51E-02 | 1 | P51648 | ALDH3A2 | More | | Clarithromycin | hsa00340 | Histidine metabolism | 3.03E-02 | 1 | P51648 | ALDH3A2 | More | | Clarithromycin | hsa00350 | Tyrosine metabolism | 4.51E-02 | 1 | P28332 | ADH6 | More | | Clarithromycin | hsa00380 | Tryptophan metabolism | 4.51E-02 | 1 | P51648 | ALDH3A2 | More | | Clarithromycin | hsa00410 | beta-Alanine metabolism | 3.03E-02 | 1 | P51648 | ALDH3A2 | More | | Clarithromycin | hsa00500 | Starch and sucrose metabolism | 1.75E-03 | 2 | O43451, P06737 | MGAM, PYGL | More | | Clarithromycin | hsa00515 | Mannose type O-glycan biosynthesis | 1.52E-02 | 1 | O75072 | FCMD | More | | Clarithromycin | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Clarithromycin | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Clarithromycin | hsa00600 | Sphingolipid metabolism | 4.56E-02 | 3 | Q9BX95, Q06136, P06280 | SGPP1, FVT1, GLA | More | | Clarithromycin | hsa00620 | Pyruvate metabolism | 2.08E-03 | 2 | P51648, P28332 | ALDH3A2, ADH6 | More | | Clarithromycin | hsa00730 | Thiamine metabolism | 1.50E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Clarithromycin | hsa00830 | Retinol metabolism | 1.08E-02 | 3 | Q9BPW9, O75911, P11712 | DHRS9, DHRS3, CYP2C9 | More | | Clarithromycin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Clarithromycin | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Clarithromycin | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Clarithromycin | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | Clarithromycin | hsa03013 | RNA transport | 1.91E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Clarithromycin | hsa03015 | mRNA surveillance pathway | 4.36E-02 | 3 | Q9BZI7, O43809, Q9H307 | UPF3B, NUDT21, PNN | More | | Clarithromycin | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | | Clarithromycin | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Clarithromycin | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Clarithromycin | hsa04064 | NF-kappa B signaling pathway | 1.86E-03 | 15 | P10415, Q13489, O00463, Q13546, P14778, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, P24522, P09341, P19875, Q06643 | BCL2, BIRC3, TRAF5, RIPK1, IL1R1, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, GADD45A, CXCL1, CXCL2, LTB | More | | Clarithromycin | hsa04071 | Sphingolipid signaling pathway | 5.28E-05 | 9 | P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, Q16539, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, MAPK14, BCL2, GAB2 | More | | Clarithromycin | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Clarithromycin | hsa04140 | Autophagy - animal | 3.72E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Clarithromycin | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | Clarithromycin | hsa04145 | Phagosome | 3.16E-02 | 2 | Q71U36, P68371 | TUBA1A, TUBB2C | More | | Clarithromycin | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Clarithromycin | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Clarithromycin | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | | Clarithromycin | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Clarithromycin | hsa04371 | Apelin signaling pathway | 1.94E-03 | 5 | P63218, Q14344, Q13485, P84022, Q16566 | GNG5, GNA13, SMAD4, SMAD3, CAMK4 | More | | Clarithromycin | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Clarithromycin | hsa04540 | Gap junction | 8.97E-03 | 2 | P68371, Q71U36 | TUBB2C, TUBA1A | More | | Clarithromycin | hsa04612 | Antigen processing and presentation | 2.84E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Clarithromycin | hsa04613 | Neutrophil extracellular trap formation | 1.54E-04 | 19 | O60603, P05164, P08246, Q9UM07, Q92769, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC2, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Clarithromycin | hsa04640 | Hematopoietic cell lineage | 1.64E-03 | 12 | P13612, P14778, P27930, P11215, P15144, P25063, P07766, P09693, P01732, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, CD24, CD3E, CD3G, CD8A, CD7, HLA-DOB, TNF | More | | Clarithromycin | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | | Clarithromycin | hsa04657 | IL-17 signaling pathway | 4.48E-03 | 5 | P07900, P49841, P14780, P01375, P01584 | HSP90AA1, GSK3B, MMP9, TNF, IL1B | More | | Clarithromycin | hsa04658 | Th1 and Th2 cell differentiation | 1.80E-05 | 12 | Q04759, P07766, P20963, P09693, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Clarithromycin | hsa04659 | Th17 cell differentiation | 1.25E-03 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | | Clarithromycin | hsa04660 | T cell receptor signaling pathway | 3.83E-05 | 14 | P01375, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | TNF, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | Clarithromycin | hsa04668 | TNF signaling pathway | 4.96E-02 | 6 | O00463, Q13546, Q13489, Q16539, Q13077, P14780 | TRAF5, RIPK1, BIRC3, MAPK14, TRAF1, MMP9 | More | | Clarithromycin | hsa04672 | Intestinal immune network for IgA production | 1.66E-02 | 3 | P10747, P13765, P13612 | CD28, HLA-DOB, ITGA4 | More | | Clarithromycin | hsa04724 | Glutamatergic synapse | 1.84E-02 | 3 | O15399, P63218, Q9NSB8 | GRIN2D, GNG5, HOMER2 | More | | Clarithromycin | hsa04730 | Long-term depression | 1.63E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Clarithromycin | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Clarithromycin | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Clarithromycin | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Clarithromycin | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Clarithromycin | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Clarithromycin | hsa04927 | Cortisol synthesis and secretion | 1.66E-02 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Clarithromycin | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Clarithromycin | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | | Clarithromycin | hsa04940 | Type I diabetes mellitus | 3.64E-02 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | Clarithromycin | hsa04970 | Salivary secretion | 4.92E-02 | 4 | P07550, P22694, Q14643, P49913 | ADRB2, PRKACB, ITPR1, CAMP | More | | Clarithromycin | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Clarithromycin | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Clarithromycin | hsa05010 | Alzheimer disease | 2.57E-02 | 5 | O15399, Q9NZJ5, Q13564, Q71U36, P21796 | GRIN2D, EIF2AK3, APPBP1, TUBA1A, VDAC1 | More | | Clarithromycin | hsa05012 | Parkinson disease | 1.68E-03 | 7 | O15239, P13073, P05141, P18848, Q13557, Q71U36, P68371 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D, TUBA1A, TUBB2C | More | | Clarithromycin | hsa05014 | Amyotrophic lateral sclerosis | 1.56E-02 | 6 | O15399, Q9NZJ5, Q71U36, P21796, P43243, P84103 | GRIN2D, EIF2AK3, TUBA1A, VDAC1, MATR3, SFRS3 | More | | Clarithromycin | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | | Clarithromycin | hsa05020 | Prion disease | 5.31E-04 | 11 | P13591, P01584, P11142, O15239, P13073, O15399, Q9NZJ5, P18848, P05141, P21796, Q71U36 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, GRIN2D, EIF2AK3, ATF4, SLC25A5, VDAC1, TUBA1A | More | | Clarithromycin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | | Clarithromycin | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Clarithromycin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.40E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Clarithromycin | hsa05132 | Salmonella infection | 1.05E-02 | 3 | Q13489, Q71U36, P68371 | BIRC3, TUBA1A, TUBB2C | More | | Clarithromycin | hsa05134 | Legionellosis | 6.38E-04 | 6 | P01584, P11215, P68104, P11142, P09341, P19875 | IL1B, ITGAM, EEF1A1, HSPA8, CXCL1, CXCL2 | More | | Clarithromycin | hsa05144 | Malaria | 4.92E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | | Clarithromycin | hsa05146 | Amoebiasis | 1.80E-05 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Clarithromycin | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | Clarithromycin | hsa05166 | Human T-cell leukemia virus 1 infection | 3.68E-02 | 6 | P27824, P30279, P21796, P84022, Q13485, Q13042 | CANX, CCND2, VDAC1, SMAD3, SMAD4, CDC16 | More | | Clarithromycin | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | | Clarithromycin | hsa05202 | Transcriptional misregulation in cancer | 2.85E-04 | 16 | Q15532, P41732, P14780, P27930, Q15744, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, Q92769, P12980, P24522 | SS18, TSPAN7, MMP9, IL1R2, CEBPE, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC2, LYL1, GADD45A | More | | Clarithromycin | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Clarithromycin | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Clarithromycin | hsa05217 | Basal cell carcinoma | 2.01E-02 | 4 | Q13635, P04628, Q9UJU2, P24522 | PTCH1, WNT1, LEF1, GADD45A | More | | Clarithromycin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Clarithromycin | hsa05310 | Asthma | 1.66E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Clarithromycin | hsa05321 | Inflammatory bowel disease | 1.14E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Clarithromycin | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Clarithromycin | hsa05323 | Rheumatoid arthritis | 1.58E-02 | 5 | P01375, P13765, P10747, P09341, O60603 | TNF, HLA-DOB, CD28, CXCL1, TLR2 | More | | Clarithromycin | hsa05332 | Graft-versus-host disease | 2.03E-03 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Clarithromycin | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | | |